Zymeworks (ZYME) Other financing activities (2021 - 2026)
Zymeworks (ZYME) reported Other financing activities of $8.7 million for Q1 2026, up 1029.15% on a YoY basis from $772000.0 in Q1 2025, and up 78.08% sequentially from $4.9 million in Q4 2025.
Zymeworks (ZYME) Other financing activities (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Other financing activities data on file, last reported at $8.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 1029.15% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (up 1431.93% YoY), and the FY2025 full-year result was $5.0 million, changed N/A from the prior year.
- Other financing activities climbed to $8.7 million in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $8.7 million in Q1 2026 to a low of -$2.7 million in Q3 2024.
- A 5-year average of $1.1 million and a median of $770000.0 in 2023 frame the typical range for Other financing activities.
- Across the five-year window, Other financing activities soared 19771.43% in 2023 and tumbled 303.31% in 2024, its largest moves.
- Tracing ZYME's Other financing activities over 5 years: stood at -$116000.0 in 2022, then soared by 763.79% to $770000.0 in 2023, then plunged by 122.6% to -$174000.0 in 2024, then jumped by 2913.22% to $4.9 million in 2025, then jumped by 78.08% to $8.7 million in 2026.
- Business Quant data shows ZYME's Other financing activities at $8.7 million in Q1 2026, $4.9 million in Q4 2025, and $28000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.72 Mn |
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 28,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | -707,000.00 |
| Jun 30, 2025 | -707,000.00 |
| Mar 31, 2025 | 772,000.00 |
| Mar 31, 2025 | 772,000.00 |
| Dec 31, 2024 | -174,000.00 |
| Dec 31, 2024 | -174,000.00 |
| Sep 30, 2024 | -2.70 Mn |
| Sep 30, 2024 | -2.70 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 770,000.00 |
| Dec 31, 2023 | 770,000.00 |